Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company that develops and commercializes novel therapies for central nervous system (CNS) disorders with significant unmet need. Its marketed products include Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol) for excessive daytime sleepiness, and Symbravo (meloxicam and rizatriptan) for acute migraine. Its pipeline targets conditions such as Alzheimer's disease agitation, ADHD, fibromyalgia, and binge eating disorder.